LONDON–(Marketwire – July 8, 2010) –   Frederic H. Moll, M.D., co-founder and executive chairman of the board of directors for Hansen Medical, Inc., will present at the Royal Society of Medicine’s (RSM) annual Medical Innovations Summit on July 11, 2010.

What: Dr. Moll will highlight the success and benefits of the company’s Sensei® X Robotic Catheter System and its Artisan™ Extend Control Catheter. The Sensei X Robotic Catheter System allows physicians to instinctively position robotic catheters in difficult anatomical locations within the heart in a stable and controlled manner. The system consists of a physician workstation capable of controlling a robotic arm, which is attached near the foot of the procedure table. The robotic arm maneuvers the Artisan Control Catheter. Studies demonstrate that use of Hansen Medical’s robotic platform help to increase safety and reduce both radiation and fluoroscopy exposure.

When: Sunday, July 11, Session 4, 12:30 – 13:30, followed by a Q&A session with all speakers.

Where: The Royal Society of Medicine, 1 Wimpole Street, London W1G0AE, UK.

About The Medical Innovations Summit 2010: The Royal Society of Medicine has always been the home of medical education and is fast becoming a vital source of information on medical innovation. The RSM is eager to ensure its members and guests are kept updated and informed on the latest developments in medicine and healthcare. This year’s program features guest speakers from around the world with an intensive focus on the latest medical breakthroughs. For additional information, visit http://www.rsm.ac.uk/innovations or contact:

Carmel Turner
Media Manager, RSM
020 7290 2904
07949516471

About Hansen Medical: Hansen Medical, Inc. (NASDAQ: HNSN), based in Mountain View, California, USA, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the European Union, the Sensei and the Sensei X systems are cleared for use during Electrophysiology (EP) procedures, such as guiding catheters in the treatment of Atrial Fibrillation (AF). The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF have not been established. Additional information can be found at www.hansenmedical.com.

Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks, and Artisan is a trademark of Hansen Medical, Inc. in the United States and other countries.

GARRISON, NY–(Marketwire – July 7, 2010) –  Aurora Information Technology (Aurora IT), a medical website design and medical marketing firm, has been hard at work this year launching a number of exciting new websites. “Nowadays, patients consults Internet first for medical information,” explained Daniel Gilbert, CEO of Aurora IT. “As medical and physician website designers, we know that the best websites contain educational and keyword-packed information in order to get found by search engines and prospective patients.” Gilbert and his team at Aurora IT successfully launched the following medical websites:

Health Options Worldwide – HOW – www.healthoptionsworldwide.com: HOW is an interactive medical tourism website that allows users to search for medical providers that offer low rates for treatments, domestically and internationally.

Dr. Ridwan – www.drridwan.com: Renowned NY urologist Dr. Ridwan Shabsigh’s new website features a new logo and a web-based men’s health program, “The Dr. Ridwan Show,” which covers common topics in men’s health.

Rockland Eye Physicians & Surgeons – www.rocklandeye.com: The new website for Rockland Eye, providers of general ophthalmology for children and adults, features patient education videos, doctor biographies, insurance information and a user-friendly contact form.

Autosafe Medical – www.autosafemedical.com: Medical device company AutoSafe Medical’s website redesign showcases their flagship product, AutoSafe Advantage™, a single safety solution that fits any needle or syringe configuration, with an auto launch product page video.

Urgent Care MDs – www.urgentcaremds.com: UrgentCareMDs’ full service, extended hours urgent care got a new website and branding that demonstrates their commitment to evidence-based quality health care.

LA Ortho Experts – www.laorthoexperts.com: LA Ortho Experts’ newly redesigned website incorporates brilliant photography and detailed conditions and treatments for the back, spine, neck, knee and shoulder. The site also has a convenient “free MRI review” form, Hot Topics and patient educational videos.

N.Y. Neurological Associates – www.nynapc.com:
The new website for this general neurology and physical therapy practice offers information common neurological conditions and treatments, physician biographies and resources such as links, affiliated hospitals, insurance information and forms.

Sockolov & Sockolov – www.sockolov.com:
Sockolov & Sockolov based in Sacramento, California, provides top-notch medical care to their community and continuous medical training to practitioners. Their Medical Research facility conducts ongoing investigational studies to address the most common and critical health challenges.

Click here to see all recent news from this company

WAYNE, PA–(Marketwire – July 7, 2010) –  Clinical and Laboratory Standards Institute (CLSI) will showcase StatisPro™, its new method evaluation software, at the AACC/ASCLS Annual Meetings and Clinical Lab Expo in Anaheim, California, from July 27 through July 29. StatisPro will make it easier for laboratory professionals to perform the statistical analysis necessary to implement recognized CLSI guidelines when evaluating a clinical method. StatisPro can be used to demonstrate that clinical methods conform to accreditation or regulatory requirements.

Developed in conjunction with Analyse-it®, StatisPro method evaluation software is easy to use, provides clear step-by-step advice on performing a study, and is the only software to faithfully implement the eight most popular CLSI method evaluation guidelines. StatisPro will be demonstrated by experts at CLSI booth #6623 during the Clinical Lab Expo.

The CLSI President’s Message session on July 26 at 10:30 AM, in the Anaheim Marriott Hotel Platinum Ballroom 7, will feature a presentation on StatisPro. Participants will have the opportunity to hear an initial perspective on the StatisPro software capabilities. The event will also include information about new strategies for point-of-care testing devices and innovations for newborn screening by tandem mass spectrometry.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information on CLSI, visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft® Excel™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 7, 2010) –  At the recent 25th Annual European Association of Urology Congress, Dr. David Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City, presented findings that showed that obesity does not adversely impact the outcomes of robotic-assisted laparoscopic prostatectomies (RALP) for prostate cancer treatment. These findings contradict the popular opinion that non-obese patients fare better than their obese counterparts after having robotic surgery for prostate cancer.

Dr. Samadi presented findings from a study that followed 1,112 men who underwent RALP for prostate cancer treatment. The results were that the perioperative, pathologic, and functional outcomes were the same regardless if the patients were obese or not. “Previously it had been thought that obese patients do not do well after RALP because of the way their high BMI affects their outcomes, but there wasn’t enough data to support that notion,” said Dr. Samadi. Ironically, previous data has shown that obese patients have worse outcomes with traditional open prostatectomy versus a robotic prostatectomy.

In fact, the new study showed that both obese and non-obese subjects had similar Gleason scores (a grading system used to predict the behavior of prostate cancer), positive margins, biochemical recurrence, and surgical complications. They had comparable operating times and approximate blood loss. Their post-operative continence rates were similar at three, six, and 12 months. Their post-operative sexual function rates were also very similar at the same stages. “While there is an increased incidence of prostate cancer in men with high BMI, the bottom line is that RALP is effective and safe for these types of patients,” Dr. Samadi said.

“The only barrier to operating on an obese patient would be the surgical challenges that arise as a result of their body mass,” explained Dr. Samadi. A typical RALP takes Dr. Samadi about 90 minutes to perform. With obese patients, surgeries can often go beyond three hours, and if the surgeon does not have the required experience with these kinds of cases, many complications such as DVT, blood clots in lower extremities or overall edema can arise. “I always recommend that a very experienced, high-volume surgeon perform the procedure,” advised Samadi.

Click here to see all recent news from this company

COLCHESTER, VT–(Marketwire – July 7, 2010) –  Competitive Computing, Inc., also known as C2, announced today that they have been selected as a preferred technology services partner by Vermont Information Technology Leaders, Inc. (VITL). VITL is a not-for-profit organization that assists Vermont physician practices and hospitals with implementation of Electronic Health Records (EHR) systems and achieving meaningful use of those systems.

“We are excited to be selected as a preferred technology services provider in partnership with VITL,” said Martin Thieret, Founding Partner, Enterprise Infrastructure Solutions. “We look forward to working with physician offices throughout Vermont to provide cost effective and secure information technologies for electronic health records and practice management systems.”

To facilitate a rapid and successful EHR implementation, C2 offers a set of standard services and preferred pricing for physician practices that include:

• EHR Technical Assessment and Recommendations
• Design, Implementation and Training
• Proactive, Ongoing Management, Security and Systems Monitoring

“VITL’s goal is to provide physician practices with carefully-selected preferred partners that they can feel confident doing business with,” said David Cochran, MD, President and CEO of VITL. “We are pleased that C2 has met our criteria and has been added to our growing list of partners,” continued Cochran.

About VITL
VITL is a non-profit organization with a mission of collaborating with all stakeholders to expand the use of secure health information technology to improve the quality and efficiency of Vermont’s health care system. www.vitl.net. 

About C2
Competitive Computing (C2) is a leading Vermont IT solutions firm that helps organizations achieve competitive advantage by leveraging advancing technology solutions. They offer a comprehensive set of IT services that includes design, implementation, protection and management of IT environments for EHR and practice management needs. C2 also provides a complementary suite of service offerings that includes Physician Practice and EHR Management, Mission-Critical Support Services, Unified Communications, Enterprise Infrastructure Services, Multi-Channel eCommerce and eGovernment Services. C2 is a women-owned, small business celebrating its 17th year in business in 2010. www.competitive.com.

Click here to see all recent news from this company

SAN JUAN, PR–(Marketwire – July 7, 2010) –  After a lull brought on by the global recession, Puerto Rico appears to be bouncing back as one of the world’s top destinations for life science companies. Two U.S. companies — Blu Pharmaceuticals and a DuPont business, Pioneer Hi-Bred — announced new manufacturing and R&D facilities on the island during the past several months.

With Amgen, Eli Lilly and Abbott Laboratories investing $4 billion in the island over the past seven years, Puerto Rico rapidly became the world’s third largest biotech manufacturer, earning it the nickname “Bio Island.” Puerto Rico also has one of the largest concentrations of pharmaceutical manufacturing operations in the world and produces 13 of the top 20 blockbuster drugs sold in the United States.

Most recently, Pioneer Hi-Bred announced a new state-of-the-art research and development facility in Salinas on the southern coast of Puerto Rico to complement its existing trial seed production facility. The $6 million facility is expected to employ 100 scientists, agronomists and others.

“Puerto Rico was a smart choice for many reasons,” said John Soper, Pioneer Vice President of Crop Genetics Research and Development. He noted that the island has the same regulatory framework as the mainland United States, a longer growing season suitable for planting crops year-round and a steady stream of quality talent coming out of the University of Puerto Rico.

Pioneer also worked closely with the Puerto Rico Industrial Development Company (PRIDCO), a governmental economic development agency, to take advantage of aggressive new economic incentives.

“The new Pioneer laboratory is exactly the kind of investment the Government of Puerto Rico has been working to foster to help move our island into R&D and other aspects of an innovation economy,” said PRIDCO’s Executive Director Javier Vázquez Morales.

Kentucky-based Blu Pharmaceuticals also opened a new generic drug manufacturing facility in Dorado in March. The company is expected to invest $60 million in the facility during the next three years and employ nearly 250 people as it manufactures seven different medicines it will supply to the U.S. government.

“The stars aligned for us in Puerto Rico,” said Bill Luster, President of Blu Pharmaceuticals. “We were able to acquire a state-of-the-art manufacturing facility for pennies on the dollar of what it would have cost for us to build an operation from the ground-up, plus we were able to tap into a highly talented workforce.”

For more information, visit www.pridco.com.

For free broadcast quality downloads of b-roll and other videos and additional press materials, visit newsinfusion.com.

id=”nav_links”>

SAN MATEO, CA–(Marketwire – July 7, 2010) –  AtHoc, Inc., the pioneer and leader in network-centric emergency mass notification systems, today announced that the United States Army Garrison Walter Reed and Walter Reed Army Medical Center (WRAMC) will deploy its award-winning AtHoc IWSAlerts™ system to help alert personnel in the event of an emergency and to rapidly communicate mission-critical information. The planned implementation of AtHoc’s technology will support as many as 10,000 military and civilian personnel at WRAMC, Walter Reed Army Institute of Research and the Armed Forces Institute of Pathology. 

The AtHoc network-centric mass notification system will be deployed onsite behind Walter Reed’s NIPRNet firewall and will run using Microsoft-based servers and databases. The AtHoc solution will use the garrison’s existing IP network services and will leverage a centralized, Web-based architecture to deliver reliable and secure emergency notifications to all personnel. The system is fully compliant with the Department of Defense’s (DoD’s) Unified Facilities Criteria and the National Fire Protection Association Alarm and Signaling Code (NFPA 72) for net-centric emergency mass notification.

The AtHoc system will deliver alerts through the telephone, with text messaging, and with intrusive audio/visual pop-up alerts to personnel connected to the IP network via desktop, laptop and any other networked device. Alert responses from recipients will be captured and reported to emergency managers in real time to provide an enterprise personnel accountability picture of the safety and status of all personnel. 

In addition to mass emergency alerting, the AtHoc system can be used for healthcare-specific scenarios such as a personnel recall in the event of mass casualty incident, or to quickly disseminate accurate information when dealing with a disease outbreak. 

AtHoc is the No. 1 provider of network-centric mass notification systems to the U.S. military and is currently deployed at 185 installations, protecting more than 1.3 million personnel worldwide. AtHoc specializes in enterprise deployments supporting entire geographically dispersed organizations — major commands, regions and services — from a private cloud application, hosted at internal DoD data centers. This new agreement is the latest in a series of significant DoD medical deployments by AtHoc. Recent deals include the U.S. Army Irwin Health Care Clinic at Fort Riley and Lyster Army Medical Clinic at Fort Rucker.

“The agreement with Walter Reed continues the successful rapid adoption of AtHoc IWSAlerts by the U.S. Army to support their command (IMCOM) emergency mass notification initiatives,” stated (Ret.) Army Col. David Brown, director of Army operations for AtHoc. “The scale of this deployment is significant as it clearly demonstrates the enterprise-class capabilities of the AtHoc platform and its ability and flexibility to address the unique requirements of an Army garrison and an Army medical center.”

AtHoc’s innovative solution represents the evolution of mass notification technology to a third generation able to leverage existing IP networks to (a) communicate emergency information rapidly to all connected devices; (b) integrate and unify disparate existing mass notification capabilities; (c) provide bi-directional communication allowing collection of feedback from all personnel; and (d) achieve enterprise-level scalability and processes. The result is the most effective enterprise-wide mass notification capability with the best cost-to-benefit ratio. 

About AtHoc
AtHoc is the pioneer and recognized leader in providing network-centric emergency mass notification systems to military, homeland security, government and commercial organizations. AtHoc’s products are used for physical security, force protection, personnel accountability, recall and regulatory compliance. Millions of end-users worldwide, in organizations such as the U.S. Air Force, U.S. Army, U.S. Navy, U.S. Coast Guard, NASA, UCLA, Microsoft, Boeing and Raytheon rely on AtHoc’s unified notification systems for their emergency alerting and critical communication needs. AtHoc has partnered with market leaders including Microsoft, Cisco, Dell, Harris, Siemens, Northrop Grumman, MIR3, Lockheed Martin and others to bring these notification solutions to the public and commercial markets.

For more information on AtHoc, please visit http://www.athoc.com.

ENGLEWOOD, CO–(Marketwire – July 7, 2010) –  BioMedical Technology Solutions Holdings, Inc. (OTCBB: BMTL) (“BMTS”) is pleased to announce that it is placing an additional Demolizer® II System in American Samoa representing its third placement in the past 30 days within the V.A. Health Network. The Demolizer® II provides a simple, safe and environmentally friendly means to manage medical waste generated in support of the care of U.S. veterans.

“With 153 large medical centers and over 700 outpatient centers, the V.A. represents an excellent opportunity for our company,” says Don Cox, BMTS’ President and C.E.O. “The placement of the third system in a short period of time represents a natural progression within the V.A. Health Network. This also further validates our plans to expand into the government and military markets.”

The Demolizer® II delivers long term cost advantages compared to traditional hauling options and improved personnel safety and facility security since hauling trucks no longer need to enter V.A. facilities. For these reasons, BMTS expects to expand product placement at V.A. facilities and outpatient clinics over the coming months.

About BioMedical Technology Solutions Holdings, Inc.

BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS’ patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS’ products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit www.bmtscorp.com or call 866-525-2687.

About the Demolizer® II

The Demolizer® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 47 states after review by 78 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.

Safe Harbor for Forward Looking Statements

The statements contained in this press release may include certain projections and forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company’s current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of BioMedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward looking statements as a result of various important factors.

ROCHESTER, MI–(Marketwire – July 7, 2010) –  OPTIMIZERx Corporation (OTCBB: OPRX) announced today that it has signed an agreement with Carilion Clinic to implement its SampleMD™ solution to allow its doctors and staff a more efficient way to search, select and distribute sample vouchers, prescription co-pay coupons and other support information right from their desktops.

Carilion Clinic is a healthcare organization with more than 600 physicians in a multi-specialty group practice and eight not-for-profit hospitals that specializes in patient-centered care, medical education and clinical research, with a goal of providing the best possible health outcome and healthcare experience for each patient. 

“Our providers are very sensitive to the costs involved when prescribing brand name medications. The SampleMD platform allows our practitioners a better way to provide sample vouchers to make sure they can tolerate any new medications prescribed or co-pay coupons to help them continue to stay on their medication,” said Howard B. Graman, MD, Carilion Clinic Chair, Primary Care and Regional Medicine.

“We are excited to launch this important initiative with Carilion Clinic to provide an integrated electronic platform that reduces workflow interruption while providing more support to more patients,” said David Harrell, Chairman and Founder of SampleMD. “It is right in line with the Carilion Clinic’s mission to provide the highest quality health care for the individuals, families, and communities they serve.”

For more information on SampleMD, go to www.samplemd.com.

About OPTIMIZERx Corporation

OPTIMIZERx provides unique platforms to help patients better afford and comply to their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient access and adherence to their products.

About Carilion Clinic

Carilion Clinic is a multi-specialty healthcare organization with more than 600 doctors and eight hospitals, based in Roanoke, Va. Led by physicians, Carilion Clinic is committed to clinical excellence, education and research. Carilion Clinic is dedicated to providing care that is centered on the patient’s needs, supported by an ongoing commitment to quality and service. With nationally recognized specialists, award-winning nurses, the latest technology and state-of-the-art facilities, Carilion Clinic is bringing tomorrow’s healthcare into focus today. For more information, please visit www.CarilionClinic.org.

‘SAFE HARBOR’

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CHICAGO, IL–(Marketwire – July 7, 2010) –  The National Council of State Boards of Nursing (NCSBN^®) Board of Directors approved an overall passing standard of 55, with no individual section of the test at a scoring level below 50, for the Pearson Test of English Academic (PTE Academic). This decision is consistent with the previous passing standards recommended for other English language tests and the level of English proficiency needed to perform entry-level nursing safely and effectively. This recommendation also supports the NCSBN policy position on international nurse immigration, which states that “domestic and international nurses need to be proficient in written and spoken English skills.”

NCSBN has approved similar passing standards on English language proficiency tests for the Test of English as a Foreign Language Computer-based Test (TOEFL CBT) in 2003 and for a version of the TOEFL Internet-based Test (TOEFL iBT^®), as well as for the International English Language Testing System (IELTS^™) examination. NCSBN is now providing its member boards with another option for evaluating English language proficiency of licensure applicants by setting a minimum English proficiency requirement with PTE Academic. Given the number of internationally educated nurses who seek licensure in the U.S., defining a legally defensible passing standard, documenting the procedures used to identify that standard, and making the standard available to boards of nursing and other interested parties is a benefit to member board jurisdictions.

PTE Academic was developed to measure the English communication skills of nonnative English-speaking students in an academic environment. Owned and developed by Pearson, the test was cross-validated in several countries, including the United Kingdom, Australia and the U.S., to ensure that the test is representative of and measures international academic English. PTE Academic measures four English language skills via integrated test items: Writing, Speaking, Reading and Listening. For more information about PTE Academic, visit http://pearsonpte.com/PTEAcademic.

“Setting an English Language Proficiency Passing Standard for Entry-Level Nursing Practice Using the Pearson Test of English Academic,” an NCSBN NCLEX Technical Brief, can be found on the NCSBN website at https://www.ncsbn.org/1233.htm.

The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also four associate members.

Mission: The National Council of State Boards of Nursing (NCSBN), composed of Member Boards, provides leadership to advance regulatory excellence for public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  EmpowHER is offering free access to world-class health information as well as a community of experts and advocates to the millions of women interested in current research on cord blood and stem cells. These resources are offered in support of the Cord Blood Awareness Month, which occurs in July and is sponsored by the American Hospital Association.

Cord blood is the blood located inside the umbilical cord after the cord has been cut. It is rich with stem cells, which have the ability to regenerate and form cells that create all other tissues, organs, and systems in the human body. The unique and special characteristics of cord blood cells provide the possibility of healing some cancers or inherited diseases. Also, according to the American Pregnancy Association, cord blood stem cells are oftentimes rejected less by the body as compared to healthy adult bone marrow stem cells. If a parent elects to do so, cord blood can be stored at the time of an infant’s delivery for medical use in the future. Some experts question the effectiveness of storing cord blood, however, as it may contain the same cells that caused a disease or medical condition in the child, the National Institutes of Health reports.

According to research published in the Journal of Reproductive Medicine, 3 out of every 4 pregnant women consider themselves only “minimally informed” about this issue.

For women wanting to learn more about this issue, EmpowHER offers invaluable content on its site where women can find topical medical articles and guides to additional online resources on cord blood and stem cell research and therapies.

To access cord blood content on EmpowHER, please click the links below:
Cord Blood Resource Page
Thinking About Cord Blood Banking?
Cord Blood Donation
Cord Blood Banking – The Medicine of the Future?
Growing New Organs From Cord Blood – Why Transplants May Not Be Needed In Future
Can Obama Cure Cancer With Stem Cell Research?

“More women need to understand what cord blood donation really entails and what the reasons behind it are,” says Michelle King Robson, EmpowHER’s Founder, Chairperson and CEO. “This way, pregnant women considering cord blood donation can make more informed decisions when offered this option at childbirth.”

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.empowher.com.

Click here to see all recent news from this company

HALLOWELL, ME–(Marketwire – July 6, 2010) – Granite Hill Estates (GHE) has added two more sessions to its Life Enrichment Series, dedicated to personal, intellectual, and spiritual enrichment. The first session — “Wills and Estates” — will be presented on Monday, July 12, 2010 at 6:00 p.m. The second session — “The Role of Physical Therapy in Improving Your Health” — will be conducted on Tuesday, July 13, 2010 at 11:00 a.m. Both sessions will be held in the Media Room at Granite Hill Estates.

“The Life Enrichment Series is a great resource for GHE residents, our families, and others in the greater Hallowell community who are interested in these important topics,” said Bob Bond, community resident director. “We are thrilled to be hosting these informative sessions.”

“Wills and Estates” will be conducted by Mark L. Fortier, Esq., co-owner of Merrill, Hyde, Fortier & Youney, P.A., a general law practice located at 95 Water Street, Skowhegan, Maine. A native of Skowhegan, Mr. Fortier earned his JD from Vermont Law School in 1984. His practice includes the areas of real estate titles and closings, preparation of wills, administration of estates, guardianship/conservatorship of adults and minors, and adoptions.

“The Role of Physical Therapy in Improving Your Health” will be conducted by Linda Princiotta, PT, owner of Bright Physical Therapy. Ms. Princiotta is a Licensed Physical Therapist, with a BS in Physical Therapy from Quinnipiac University in Hamden, CT (1987). She’s a member of the American Physical Therapy Association; a Certified Clinical Instructor; a Certified Personal Trainer; and a member of the International Sports and Fitness Trainers Association. She lives in Pittson.

To get to Granite Hill Estates, take exit 109 from the south or 109B from the north off I-95 (Winthrop). Head west on Route 202. Take a left onto Edison Drive. GHE is on the right.

About Granite Hill Estates
GHE is a continuing care retirement community (CCRC) in the heart of the Kennebec Valley. Offering cottage homes and apartments, GHE provides a full complement of amenities and services, including an indoor heated swimming pool; a fully equipped fitness center; snow shoveling, lawn care, and exterior home maintenance; housekeeping; and appliance maintenance. GHE received its CCRC designation from the Maine Bureau of Insurance in November of 2004. And GHE provides a complete continuum of care, on campus, through MaineGeneral Health. For additional information, please visit www.granitehillestates.com.

SPRINGFIELD, OH–(Marketwire – July 6, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed its previously announced sale of 1,714,286 shares of common stock at $3.50 per share, resulting in gross proceeds to the company of $6.0 million. 

AdCare expects to receive net proceeds of approximately $5.4 million, after deducting underwriting discounts, commissions, legal fees and other offering-related expenses payable by the company. As previously announced, AdCare has granted a 30-day option to the underwriter to purchase up to an additional 15% of the shares offered, or 257,143 shares, to cover over-allotments, if any. 

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes.

C.K. Cooper & Company acted as the sole manager for the public offering.

The shares were offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. Copies of the prospectus supplement and accompanying base prospectus, which form a part of the effective registration statement, have been filed with the SEC and may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus supplement and accompanying base prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include, among others, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

NEW YORK, NY–(Marketwire – July 6, 2010) –  In its ongoing effort to keep clients and key partners at the forefront of health promotion strategies in the workplace, Plus One hosted its annual Wellness Roundtable at the Cisco campus in San Jose, California today. Themed “Wellness Rx for the Future: Healthy Lifestyles as Medicine,” the event provided leaders from across the country the opportunity to explore how the most progressive companies and experts approach their employee wellness programs while achieving the greatest return on investment. 

Dr. Pam Hymel, Cisco’s Corporate Medical Director, led off the panel and discussed how Cisco executes on their vision for “enhancing the health and well-being of employees and their families leading to healthier, more fulfilling lives and greater productivity.” Through their comprehensive HealthConnections program, Cisco has created a vehicle to determine the most prevalent risk factors among their population, deliver targeted programs for engagement, and offer a single point of origin for family healthcare. 

Next, Dr. Kerry Olsen, Medical Director for Mayo Clinic’s Dan Abraham Healthy Living Center, reiterated the importance of the event’s theme that “exercise is medicine.” He shared how he and his team execute on their goal to “reach the hard to reach employees” and motivate them towards healthier lifestyles by focusing on the body, mind, and spirit. Through the Healthy Living Center’s utilization incentives, a direct correlation has been seen in risk factor reduction among Mayo’s population.

Ken Shachmut, Senior Vice President of Strategic Initiatives, Health Initiatives & Re-engineering for Safeway, closed the panel portion of the event. He shared how Safeway has been able to stand alone in holding their healthcare costs flat for the past five years through incentive based programs and more transparent employee communications. Comparing healthcare costs to Safeway’s core business, Ken asked attendees: “After you go grocery shopping, are you ever told you will receive a receipt after 30 days with the cost of purchase?”

Those attending the event took full advantage of the networking opportunities the setting provided, as well as toured the world class Cisco LifeConnections Health Center and Fitness Center managed by Plus One. Mike Motta, Plus One Co-Founder, President and Chief Executive Officer, hailed the success of the event: “The speakers today are testament to the power regular physical activity and comprehensive wellness programs can have on the health not only of a corporation’s employees, but their bottom line as well. I am proud that we were able to deliver an event like this for our clients and look forward to continuing to provide wellness solutions that deliver results.”

About Plus One
Plus One Health Management Inc. is a leading provider of comprehensive wellness solutions for corporations and other discerning organizations. From the design, development, and management of on-site wellness centers, to the creation and execution of results-focused employee wellness programs, to the five-star delivery of hospitality spa and fitness services, Plus One applies an integrated approach to individual and employee wellness. Clients include Fortune 500 companies, financial services firms, law partnerships, and world leaders in the media, biotechnology, energy, and pharmaceutical industries. Founded in 1986, today Plus One employs more than 1,500 professionals nationwide. For more information, please visit www.plusonehealthmanagement.com.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – July 6, 2010) –  International Stem Cell Institute (ISCI, http://www.iStemCelli.com) announced today a major breakthrough in stem cell therapy providing new hope for those suffering with Parkinson’s disease in the US and worldwide. The procedure using placenta stem cells is reversing current medical thinking which relies heavily on the use of drugs and surgery. This new advancement in medicine may be a significant step in the long sought after cure for Parkinson’s disease. Compared to prior medical procedures, ISCI’s proprietary stem cell therapy for Parkinson’s patients is showing immediate beneficial effects for many patients, and at a cost most families can afford.

Why Surgery Is Expensive and Risky
In one of the largest FDA approved randomized controlled studies, new Parkinson’s research shows motor functions in patients with very advanced symptoms can be improved with brain surgery. The study just published in the June 3 New England Journal of Medicine reports beneficial results from deep brain stimulation (DBS), an extreme and invasive surgical procedure which until now has been one of the most effective weapons in the war on the disease. However, International Stem Cell Institute (ISCI), a leading US based organization in stem cell therapies and regenerative medicine, believes Parkinson’s symptoms can be alleviated — almost to the point of full restoration — using placenta stem cells. Administering these stem cells, an easy and painless treatment, avoids the risks and costs of surgery. And unlike the wait for future drugs and clinical trials, stem cell treatment for Parkinson’s is not years off in the future but available to Parkinson’s sufferers right now.

Potential Drawbacks to DBS
One of the most serious adverse effects from DBS is intracranical hemorrhaging. The risk of hemorrhage closely correlates with the number of microelectrode passes used to determine the target location, with experts claiming it’s better to do more passes than less to be sure of where the electrodes are placed. “This kind of surgery requires many specialists, a Parkinson’s disease expert, a surgeon very skilled in stereotactic functional neurosurgery, a radiologist to precisely locate the target, and a physiologist for microelectrode placement and reading,” according to Rita Alexander, ISCI executive director. “Setting the stimulation parameters can take several hours, and more time is required for repeat evaluations to make certain the settings are correct. Clearly this procedure is very costly, risky, and can run $60,000 or more per patient. There may be negative consequences of targeting as well, including cognitive and psychological changes in patients.”

Treating Parkinson’s with Stem Cells Can Stop The Shaking, Restore Movement
“At ISCI we’ve successfully treated over 3,000 patients with many serious chronic diseases and we’re putting a huge focus on helping Parkinson’s patients. Our procedure represents a dramatic new advance in treating the disease, we’re seeing outstanding improved functions in advanced patients who can’t be satisfactorily controlled with drugs or high risk surgery,”  says Anderson. The therapeutic results from placental adult stem cell therapy is clearly effective at relieving the symptoms, and can provide a better quality of life for those in moderate to severe stages of the disease. ISCI is currently offering Parkinson’s patients the opportunity to undergo these innovative, less painful and less invasive medical treatments at a reasonable cost compared to brain surgery. “The families and individuals we work with are reporting truly amazing results,” Anderson maintains. “Some patients show amazing recovery from the nonstop shaking, regaining their balance and fluidity of motion. Their overall color is better and in some cases full range of movement is being restored.” Remarkably patients are recovering their ability to speak, to use handwriting and utensils, and showing decreasing problems with incontinence, swallowing and drooling. The International Stem Cell Institute is committed to providing innovative, long-term solutions for patients with chronic diseases ranging from cardiovascular disease and stroke, cerebral palsy, diabetes, autoimmune diseases such as RA and more.

Parkinson’s patients and their families are encouraged to contact ISCI directly at www.istemcelli.com/parkinsons.html

About ISCI (www.iStemCelli.com) ISCI is a leader in stem cell therapy and regenerative medicine dedicated to restoring vibrant health and quality of life for thousands of people with degenerative diseases around the world. Over 3000 patients have safely undergone stem cell treatments. The company has a global reach and is dedicated to the highest medical and ethical standards.

Disclaimer: Stem Cell Therapies offered for consideration by International Stem Cell Institute are not currently approved by the FDA and the treatments and procedures mentioned take place outside the USA.

Stem Cell Treatments are not a cure for any condition, disease or injury, nor a substitute for proper medical diagnosis and care. The information contained in this press release and ISCI’s written materials should not be considered medical advice. It is intended to be used for educational and information purposes only.

Click here to see all recent news from this company

KANSAS CITY, MO–(Marketwire – July 6, 2010) –  Academic institutions across the United States are playing a critical role in developing life-saving treatments, procedures and innovations, and must be supported by a public policy agenda designed to foster continued growth and investment, U.S. Secretary of Health and Human Services Kathleen Sebelius told a gathering of leaders from the public and private sectors here today. Friends of Cancer Research, Kansas Bioscience Authority, The University of Kansas Cancer Center, Ewing Marion Kauffman Foundation, and Council for American Medical Innovation convened today’s symposium titled The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results.

The program also included a moderated discussion with Dr. Francis Collins, director of the National Institutes of Health (NIH), and Dr. Margaret Hamburg, commissioner of the Food and Drug Administration (FDA) on agency perspectives to fostering innovation and increased collaboration. The discussion was moderated by former U.S. House Majority Leader and Chairman of the Council for American Medical Innovation, Richard Gephardt.

“This is a rare opportunity for anyone involved in cancer research and drug development,” said Roy A. Jensen, M.D., director of The University of Kansas Cancer Center. “To have so many key policy makers, academics, industry-leaders, and the non-profit community represented, discussing ways to drive new collaborations is extraordinary. As universities’ appetites for commercializing research grow and high-throughput platforms are increasingly adopted in public research programs, we seem to be seeing a new paradigm for drug discovery. We feel The University of Kansas Cancer Center is leading this effort in the new innovation ecosystem.” 

The day-long town hall, a result of collaboration between several like-minded organizations, explored drug development from the perspectives of thought-leaders from academia, government, industry and the nonprofit sector.

“This town hall, and the participation by scientific leadership at the highest levels, is an important step toward much-needed increased interagency collaboration,” said Dr. Ellen Sigal, chair, Friends of Cancer Research. “The proposals discussed today will accelerate the process to help get scientific breakthroughs to patients. Without collaboration among all agencies and academic centers, the full potential of biomedical research may be stifled.” 

“Discoveries from our academic labs fuel millions of jobs, spur small business, and promote innovation. The time is right for a fundamental re-examination of the changing role of academic institutions in the innovation process,” said Tom Thornton, president and chief executive officer, Kansas Bioscience Authority.

About Friends of Cancer Research

Friends of Cancer Research (Friends) is a cancer research think tank based in the Washington, D.C. area. Working with the entire cancer research and advocacy community, Friends pioneers innovative public-private partnerships, organizes critical policy forums, educates the public, and brings together key stakeholders to overcome the barriers standing between patients and the most promising cancer treatments.

About The University of Kansas Cancer Center

At The University of Kansas Cancer Center, we are more than an academic cancer center; we are a unique community-based cancer research and care partnership focused on one mission: eliminating the burden of cancer. The University of Kansas Cancer Center is transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our nationally accredited patient care program.

About the Ewing Marion Kauffman Foundation

The Ewing Marion Kauffman Foundation is a private nonpartisan foundation that works to harness the power of entrepreneurship and innovation to grow economies and improve human welfare.

About the Council for American Medical Innovation

The United States faces serious challenges to maintaining its leadership position in innovation. The Council for American Medical Innovation is bringing together leaders in research, medicine, public health, academia, education, labor, investment and business, who are working in partnership toward a national policy agenda aimed at preserving U.S. leadership in medical innovation. American medical innovators create millions of high-paying jobs, and their discoveries are integral in the fight to cure cancer and other illnesses. The Council for American Medical Innovation views leadership in medical innovation as a key part of America’s economic recovery, future prosperity and health.

About the Kansas Bioscience Authority

The KBA is a $581 million initiative that is advancing Kansas’ national bioscience leadership by building world-class research capacity; fostering the formation and growth of bioscience startups; supporting expansion of the state’s bioscience clusters; and facilitating industrial expansion and attraction.

Click here to see all recent news from this company

FOOTHILL RANCH, CA–(Marketwire – July 6, 2010) –  Medical Marijuana Inc (PINKSHEETS: MJNA) reports significant progress on staffing of The Hemp Network. President Don Steinberg states, “In the past, Bruce Perlowin and I have created a global network of over 125,000 agents in 50 countries. We have the experience in all aspects of running a global MLM. Now we are in this new, exploding industry with a team of Doctors, immunologists, PhDs, and world renowned nutritionists to round out the products division. We have top network marketers signed up who have already created hundreds of web sites to support this new company. Alexa has rated ‘The Hemp Network’ website in the top 2%. This is after only 2 months which shows the power of this new opportunity. Our proprietary MLM software is nearing completion with a pay plan that is revolutionary. To participate in daily conference calls which discuss the pay plan, upcoming events and exchange of ideas, call 218-339-3600 PIN: 321677. Calls are held Monday through Thursday at 6:00 PM (PDT), which we invite the public to attend.”

Bruce Perlowin, CEO, stated, “The opportunity to be involved in the 1^st hemp network marketing company in history in which an existing culture of numerous movements already exist who are passionate about hemp is irresistible. Hemp enthusiast movements include the medical marijuana movement, the marijuana legalization movement, the hemp movement itself, the health, wellness and anti-aging movement, the environmental movement and the green movement. These existing cultural creative movements all herald the wonders of hemp in their various areas and are all natural and highly motivated individuals ripe to participate in The Hemp Network.”

SOLUTIONS

Medical Marijuana Inc has developed a suite of solutions to deliver an efficient and secure infrastructure for the Medical Marijuana Industry which provides the tools to industry operators to effectively manage their business with the confidence that they are in full compliance.

MEDICAL MARIJUANA INC’S TURNKEY COLLECTIVE SOLUTION

Medical Marijuana Inc’s Turnkey Collective Solution ensures that collectives operate within the guidelines of all laws and regulations regarding the tracking of the cannabis from grow cycle to final distribution. By employing Medical Marijuana Inc’s closed loop, patent pending, tracking system, it can be shown to authorities and collectives alike that the source of their supply was an active member of the collective.

TAX COLLECTION

MJNA’s Stored Value Platform System provides verifiable solutions to manage the difficult task of revenue and taxation collection. The customers of the dispensary are issued a plastic debit card or medical revenue card. The ease of access to certifiably secure transactions lessens the risk of loss at each level of the transaction.

ABOUT MEDICAL MARIJUANA INC

Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion, thus opening the door for safe and lucrative investment opportunities.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.

NEW YORK, NY–(Marketwire – July 6, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, has agreed to acquire a medical manufacturing company on multi-year terms that include benchmarks of a first year profit target range of $300,000-$600,000 and a second year target range of $600,000-$900,000. These numbers do not include the benefits of reinvestment by the company in (a) manufacturing, (b) existing company products, and (c) reduction of outstanding shares through company purchases. As a result, the medical manufacturing profits can potentially have a multiplier effect on the Company’s earnings per share.

The Company will continue to provide additional details as its acquisition strategy continues to unfold.

“We are pleased to provide this acquisition update showing the significant benefit that can accrue for the Company and stockholders,” said Alan Grofe, President.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  The Platelet Rich Plasma Treatment (PRP) is a non-surgical method that regenerates ligaments and treats chronic pain. Dr. Michael Cronin says, “During a Platelet therapy procedure the patient’s blood is drawn and put into a centrifuge which separates the plasma containing the essential platelets from the unneeded red blood cells. The PRP solution is carefully injected back into the patient’s injury area. The concentrated injection stimulates (mimics) the healing process through growth factors contained in the platelets.”

Dr. Michael Cronin was recently featured on the front cover of the Top Doctors of April 2010 in the April issue of Phoenix Magazine. Dr. Cronin is well known in Scottsdale for treating golfers for pain and injury recovery. “We often see multiple joint dysfunctions in our golfers. Our golfers are itching to get back on the course. Depending on the severity of the injury, utilizing Platelet Therapy, we can get them comfortable and moving again pretty quickly.”

Media attention first came to the revolutionary PRP treatment when Tiger Woods used it successfully to speed his recovery after surgery to his left knee. Woods was able to play in all four majors after four treatments of PRP. Tiger Woods has spoken openly about the success of his PRP Treatment in press conferences.

“PRP Treatment is no longer reserved for the elite,” states Dr Cronin. “We are having great success with our Golfers right here in Scottsdale.” In addition to sports injuries, PRP is useful for musculoskeletal pain, back pain, golfer’s elbow, rotator cuff tear, torn meniscus, strained tendons, ligaments and degenerated discs.

PRP Therapy is a major component of the healing process that Dr. Cronin prescribes. “If our Golfers want to be back on the course faster, we must attack the cause of the pain in a multi-faceted approach,” Cronin continues.

Michael Cronin, NMD, DAAPM, is a Diplomat of the American Academy of Pain Management and Founder of Southwest College of Naturopathic Medicine in Tempe, Arizona. “Treating pain effectively and achieving complete recovery is an important part of what we do here. PRP has given hope to those whom only a few years ago had very limited options to recovery,” says Dr. Cronin.

A short series of treatments is normal. The goal is to repair the injured areas, not just relieve the pain. The procedure does not create much discomfort and is recommended over the traditional use of cortisone injections.

For more info: www.plateletAZ.com

OXFORD, UK–(Marketwire – July 6, 2010) –

Mirada Medical Limited
(“Mirada” or “the Company”)

Mirada Medical Releases Casebook Software Upgrade for Medical Imaging Presentations

Oxford, UK and Ohio, US, 6 July 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, today announces that it has released a software upgrade for Casebook (Casebook 1.1.), Mirada’s unique presentation tool for showing medical scans in Microsoft PowerPoint (“PowerPoint”).

Casebook 1.1 works as a plug-in to PowerPoint and uniquely supports fully triangulated multi-planar reconstruction (“MPR”) viewing of single or fused medical images. The new software may be used as a standalone program but also offers full integration with Mirada’s clinical products including XD3, Mirada’s powerful multi-modality image analysis application. Casebook 1.1 enables users to present case information derived from imaging studies clearly and professionally. The software also offers new image visualisation options and easy-to-use editing functions.

Commenting on today’s announcement, Chief Executive Officer, Hugh Bettesworth said: “Casebook provides an easy-to-use solution to a routine problem encountered by clinicians, researchers, academics, students and all who regularly show medical images using PowerPoint. Casebook comprehensively enhances these presentations by adding support for many of the image visualisation features which were previously the preserve of dedicated reading software.”

Casebook 1.1 is available to download free of charge from the Casebook website: www.mirada-casebook.com

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada directly and also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.